Lycia Therapeutics (Nasdaq: LYCA) is a clinical-stage biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune, inflammatory, and allergic conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In October 2026, Lycia completed an initial public offering, and its common stock now trades on the Nasdaq Global Select Market under the ticker symbol “LYCA.” Lycia is headquartered in South San Francisco. Visit https://lyciatx.com/ for more information.
Lycia is hiring a Head of Investor Relations to build the function following the company's initial public offering. Title will reflect the experience of the person hired. The role reports to the Chief Financial Officer and works closely with the Chief Executive Officer and the executive team. This leader will manage Lycia's relationships with investors, sell-side analysts and banking partners, and will shape how the company's science, clinical progress and financial position are communicated to the market. It is a hands-on role for someone who wants to build a public company IR program from the ground up.